<DOC>
	<DOCNO>NCT02243371</DOCNO>
	<brief_summary>The primary objective study compare overall survival ( OS ) subject previously treat metastatic pancreatic cancer treat cyclophosphamide ( CY ) /nivolumab/GVAX pancreas vaccine follow nivolumab/CRS-207 ( Arm A ) subject treated CY/GVAX pancreas vaccine follow CRS-207 ( Arm B ) .</brief_summary>
	<brief_title>GVAX Pancreas Vaccine ( With CY ) CRS-207 With Without Nivolumab</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Age â‰¥18 year . Have histologically cytologicallyproven adenocarcinoma pancreas . Patients mixed histology exclude . Have metastatic disease . Have fail 1 prior chemotherapy regimen metastatic pancreatic cancer . Patients presence least one measurable lesion . Patients acceptance tumor biopsy accessible lesion baseline treatment lesion biopsied acceptable clinical risk ( judged investigator ) . ECOG performance status 0 1 . Life expectancy great 3 month . Patients must adequate organ marrow function define studyspecified laboratory test . Must use acceptable form birth control study . Ability understand willingness sign write informed consent document . know history evidence brain metastasis . Had surgery within last 28 day Have receive nononcology vaccine therapy use prevention infectious disease include seasonal vaccination within 28 day study treatment . Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 , GVAX CRS207 Systemic steroid within last 14 day Use 3 g/day acetaminophen . Patients immunosuppressive agent . Patients receive growth factor within last 14 day Known allergy penicillin sulfa . Severe hypersensitivity reaction monoclonal antibody . Have artificial joint implant easily remove Have evidence hepatic cirrhosis clinical radiographic ascites . Have significant and/or malignant pleural effusion Infection HIV hepatitis B C screen Significant heart disease Conditions , include alcohol drug dependence , intercurrent illness , lack sufficient peripheral venous access , would affect patient 's ability comply study visit procedure Unable avoid intimate contact another individual know high risk listeriosis ( e.g. , newborn infant , pregnant woman , HIVpositive individual ) course CRS207 treatment completion antibiotic regimen . Are pregnant breastfeeding . Have rapidly progress disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>